How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Features & Analysis
Pharma & Biotech
Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.